Stifel analyst Paul Matteis said each epileptologist he talked to at the American Epilepsy Society meeting said that patients are frequently asking for GW Pharmaceuticals’ Epidiolex. Additionally, the doctors he spoke to said they are already writing prescriptions for the drug. Early headaches with GW’s specialty pharmacy hub, which were cited by a few physicians, appear to have been addressed by the company, added Matteis, who reiterated his Buy rating on GW Pharmaceuticals shares following the AES meeting.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.